{"id":30601,"date":"2025-04-24T06:47:32","date_gmt":"2025-04-24T04:47:32","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2025\/04\/24\/mrna-vaccines-mirna-based-controlled-biodistribution-and-directed-adjuvantation-byron-brook\/"},"modified":"2025-04-24T06:47:32","modified_gmt":"2025-04-24T04:47:32","slug":"mrna-vaccines-mirna-based-controlled-biodistribution-and-directed-adjuvantation-byron-brook","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2025\/04\/24\/mrna-vaccines-mirna-based-controlled-biodistribution-and-directed-adjuvantation-byron-brook\/","title":{"rendered":"mRNA vaccines: miRNA-based controlled biodistribution and directed adjuvantation. Byron Brook"},"content":{"rendered":"<div>\n<p><b>Trends Immunol<\/b>. 2025 Apr 22:S1471-4906(25)00078-X. doi: 10.1016\/j.it.2025.03.004. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>The development of ionizable mRNA-lipid nanoparticle (mRNA-LNP) nucleic acid carriers facilitated the clinical translation of the Coronavirus 2019 (COVID-19) mRNA vaccines BNT162b2 and mRNA-1273. Here, we discuss insights into rational improvements to mRNA vaccines, focusing on LNP modifications for mRNA-LNP biodistribution control, miRNA-based biodistribution control of encoded transcripts, and precision adjuvantation strategies.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40268657\/?utm_source=WordPress&amp;utm_medium=rss&amp;utm_content=100966032&amp;ff=20250424004730&amp;v=2.18.0.post9+e462414\">40268657<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1016\/j.it.2025.03.004\">10.1016\/j.it.2025.03.004<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Trends Immunol. 2025 Apr 22:S1471-4906(25)00078-X. doi: 10.1016\/j.it.2025.03.004. Online ahead of print. ABSTRACT The development of ionizable mRNA-lipid nanoparticle (mRNA-LNP) nucleic acid carriers facilitated the clinical translation of the Coronavirus 2019 (COVID-19) mRNA vaccines BNT162b2 and mRNA-1273. Here, we discuss insights into rational improvements to mRNA vaccines, focusing on LNP modifications for mRNA-LNP biodistribution control, miRNA-based &#8230; <a title=\"mRNA vaccines: miRNA-based controlled biodistribution and directed adjuvantation. Byron Brook\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/04\/24\/mrna-vaccines-mirna-based-controlled-biodistribution-and-directed-adjuvantation-byron-brook\/\" aria-label=\"Read more about mRNA vaccines: miRNA-based controlled biodistribution and directed adjuvantation. Byron Brook\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42,68],"tags":[],"class_list":["post-30601","post","type-post","status-publish","format-standard","hentry","category-publicaciones","category-trends-in-immunology"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/30601","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=30601"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/30601\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=30601"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=30601"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=30601"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}